Hawaii Biotech starts dengue vaccine trial
This article was originally published in Scrip
Executive Summary
The private concern, Hawaii Biotech, has initiated a dose escalation Phase I clinical study with its monovalent dengue fever vaccine candidate at the US Saint Louis University Center for Vaccine Development.